EGFR and lung carcinoma: Because HER3 facilitates EGFR-TKI resistance, our results indicate that the STAT3 blockade is a promising strategy that can be employed to eradicate EGFR-TKI-resistant lung cancers, including KRAS-mutant A549 and T790 M-mutant H1975 cells.